Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HVO.L
HOLDhVIVO plc · Healthcare · United Kingdom · $63M · Avg Vol: $109K/d
COMPANY DESCRIPTION
hVIVO plc is a rapidly growing contract research organization (CRO) and the global market leader in human challenge clinical trials and laboratory services. The company boasts specialized quarantine clinics and a proprietary library of challenge viruses, serving global pharmaceutical and biotech companies. hVIVO is highly profitable and benefits from growing global investment in infectious disease vaccines and antivirals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.0M | 74.0M | 82.8M | 61.7M | -1.2% | 65.5M | 66.5M | 72.9M | 8.7% |
| EPS | -0.00 | 0.03 | 0.02 | -0.01 | -34.0% | -0.01 | -0.01 | -0.00 | — |
| Shares | 671.0M | 680.4M | 680.4M | 687.0M | +2.4% | 688.4M | — | — | — |
| Debt | 2.1M | 16.5M | 17.0M | 19.5M | 111.5% | 19.5M | — | — | — |
| Equity | 26.7M | 45.3M | 59.0M | 50.4M | 23.6% | — | — | — | — |
| Op CF | 21.1M | 22.8M | 13.6M | -19.0M | -19.6% | -19.0M | — | — | — |
| Inv CF | -1.8M | -5.3M | -0.9M | -14.3M | — | — | — | — | — |
| Fin CF | -2.4M | -6.2M | -3.2M | -6.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HVO.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HVO.L | hVIVO plc(you) | $63M | 36 | HOLD |
| ABDX.L | Abingdon Health Plc | $34M | 41 | HOLD |
| CLBX.L | CelLBxHealth plc | $39M | 16 | STRONG SELL |
| EDX.L | EDX Medical Group Plc | $65M | 6 | STRONG SELL |
| GDR.L | genedrive plc | $28M | 16 | STRONG SELL |
| POLB.L | Poolbeg Pharma PLC | $63M | 24 | SELL |
| CREO.L | Creo Medical Group PLC | $87M | 31 | SELL |
| PXS.L | Provexis plc | $39M | 44 | HOLD |
| STX.L | Shield Therapeutics plc | $86M | 21 | SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.9%